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Abstract 8 
Current information about the nutritional composition of milk fat is required for the consumer and therefore 9 
essential for the successful development of dairy industries as well as marketing their products. The progress 10 
in the knowledge concerning some milk fat components that possess biological properties and health benefits 11 
beyond their nutritional significance, have a growing interest in the dairy industry to design and formulate 12 
products that incorporate specific bioactive components derived from milk.  13 
In the last two decades, special attention has been paid to the fatty acid (FA) composition on all short, 14 
medium chain and branched fatty acid as well as linoleic conjugated acid (CLA) in milk and dairy products. 15 
Trans monounsaturated fatty acids profiles from dairy fat has gained increasing relevance because may have 16 
metabolic properties distinct from those of other origins, hydrogenation reaction for instance. Other minor 17 
lipid compounds with biological activity, phospholipids and cholesterol are part of the fat globule membrane. 18 
This review summarizes the current knowledge in milk fat research with a brief overview of the importance 19 
of dairy lipids as biological molecules with emphasis in the different bioactive compounds present in this 20 
fraction. 21 
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I. INTRODUCTION 31 
 32 
Lipids are one of the most important components of milk in terms of physical, organoleptic and nutritional 33 
properties they impart to dairy products.  However, as result of their content in saturated fatty acids and 34 
cholesterol, nutritionists have advised against consumption of milk fat. Nevertheless in the last decade it have 35 
been reported the presence in milk fat of lipid compounds that exert important biological activities as butyric 36 
acid, conjugated linolenic acid (CLA), sphingolipids as constituents of the milk fat globule membrane and 37 
liposoluble vitamins. These compounds have commercial application in the development of functional foods 38 
to promote human health and diseases prevention. In order to enhance their activity and therefore the positive 39 
effects of its consumption many studies are focused to obtain natural enrichment dairy products as well as 40 
isolation of these compounds to be used as functional ingredients. A deeper knowledge on the regulation of 41 
the metabolic pathways of these bioactive lipids and their potential positive effect in human heath will be 42 
essential in the formulation of these products with added value.  43 
In milk, lipids are present in the form of globules, with an average diameter of 3 µm in sheep milk to 5 µm 44 
in cow milk [1]. Fat globules contain a hydrophobic lipid core, consisting mainly of triglycerides (TAG), 45 
surrounded by a membrane mainly compose of phospholipids and glycoproteins. The structure and 46 
composition of the milk fat globule membrane (MFGM) is similar to all ruminant species and it represents 47 
approximately 1% of total milk fat volume [2]. Among the main health beneficial components of MFGM are 48 
cholesterolemia-lowering factor and anticarcinogenic agents [3] which allow considering MFGM as a 49 
potential nutraceutical. Furthermore milk lipids are carriers for important vitamins as A, D, E y K and 50 
carotenoids.  51 
 52 
II. TRIACYLGLYCERIDES (TAG) 53 
TAG constitutes the biggest group of milk fat lipids (nearly 98%), including a large number of esterified 54 
fatty acids. TAG in milk fat present a wide range of molecular weights when distributed according to the 55 
number of carbon atoms (taking into account the sum of the carbon atoms of the three acyl radicals) from 56 
C26 to C54 [4]. Sheep and goat’s milk have a higher percentage of medium-chain TAG (C26-C36) than 57 
cow’s milk and a lower proportion of long chain TAG (C46-C54) [5]. Compared with TAG containing 58 
mainly long chain fatty acids those comprising saturated fatty acids with 6-10 carbons have lower melting 59 
points, smaller molecule size, and less energy dense. These chemical and physical properties affect their 60 
absorption and metabolism.  61 
Given the great variance of fatty acids in milk fat, interest in the biological effects of the position occupied by 62 
individual fatty acids on the TAG molecule and the lipoprotein metabolism remains intense because may be 63 
relevant to their effects on CVD. The FA distribution in the TAG is species specific and nonrandom, with 64 
most of the C4:0 and C6:0 esterified to the sn-3 position and the C16:0 occupies the sn-2 position. As the 65 
pancreatic lipase in the gut selectively hydrolyzes TAG at the sn-1 and sn-3 positions, short free fatty acids 66 
and 2-monoglycerides are produced. This unique position of C16:0 ensures that calcium in milk is highly 67 
absorbable.  68 
 69 
III. MILK FATTY ACID COMPOSITION 70 
 3 
Milk fat is a complex mixture of about 400 different fatty acids from 4 to 26 carbon atoms although only 71 
30 of these compounds are in a concentration above 0.1% and the rest are present in trace amounts [6]. 72 
Saturated (SFA) or unsaturated (with one to four double bonds), are mostly of even number of carbon atoms 73 
but there is also odd-numbered moieties (2%) as well as branched chain fatty acids. Milk from different 74 
species have characteristics fatty acid compositions: The content in short chain fatty acids: butyric (C4:0), 75 
caproic (C6:0), caprilic (C8:0) and capric (C10:0) acids are 2-3 fold higher in sheep than in goat’s milk [7].  76 
The five major acids from the quantitative point of view (C18:1, C16:0, C10:0, C14:0, and C18:0) account 77 
for more than 70% of the total fatty acids. The content of SFA in milk fat (~ 65%) has been associated with 78 
increments in the cardiovascular disease markers in plasma as LDL-cholesterol. On the other hand, only one 79 
third of SFA in milk, C12:0, C14:0 y C16:0 seems to be unhealthy when associated to an excessive 80 
consumption [8]. Recent studies have revealed that is more important to maintain a good balance among 81 
different fatty acids than the possible healthy or harmful effects they could exert individually [9,10,11,12]. 82 
Other studies concluded that those compounds considered as hypercholesterolemic may even have positive 83 
effects in moderate intake [13] and a recent meta-analysis of prospective epidemiologic studies [14] showed 84 
that there is no significant evidence for concluding that dietary saturated fat is associated with an increased 85 
risk of CHD or CVD.  86 
Concerning to short chain fatty acids, beneficial effects of these compounds have been reviewed [15]. 87 
These authors reported the capacity of those fatty acids to reduce body weight and mainly body fat.  They are 88 
particularly digestible, as they are hydrolysed preferentially from the TAG and transferred directly from the 89 
intestine to the portal circulation without resynthesis of TAG. Furthermore, these fatty acids are a preferred 90 
source of energy ( -oxidation). Given in moderate amounts, in diets with not high fat supply, they may 91 
actually reduce fasting lipid levels more than oils rich in mono- or polyunsaturated fatty acids [16]. The 92 
butyric acid (C4:0) is present in milk fat in concentrations ranged 2-5% and it has been described as an 93 
anticarcinogenic agent. At low concentrations butyric acid can inhibit growth in a wide range of human 94 
cancer cell lines [17] although it have been shown in animal studies that dietary fibers, which liberate a 95 
constant and elevated supply of butyrate to the colon, are most effective for prevention of chemically induced 96 
colon tumors. Furthermore, synergism between butyrate and other dietary components and common drugs in 97 
reducing cancer cell growth have also been shown [18]. On the other hand, the short and medium chain fatty 98 
acids (C4:0, C6:0, C8:0 and C10:0) can exert antimicrobial and antiviral activities both in vitro and in animal 99 
studies [19]. 100 
Stearic acid (C18:0) with an average concentration in milk fat of 11%, is considered as neutral from the 101 
point of view of human health and can reduce plasma cholesterol as well as oleic acid (C18:1 cis 9, 15-23% 102 
in milk fat). It is also interesting the presence of polyunsaturated fatty acids (PUFAs) as linoleic (18:2 cis 9, 103 
cis 12) and linolenic acids (18:3 cis 9, cis 12, cis 15) in amounts of 1-3% respectively and recognized 104 
positive effect on cardiovascular health. Finally indicate that milk is the main source of conjugated linoleic 105 
acid (CLA) in the diet. It is known that the major CLA isomer (18:2 cis 9, trans 11) is a potent natural 106 
anticarcingenic agent [20]. 107 
Besides that, milk fat has other fatty acids as the branched chain fatty acids as 13-methyl tetradecanoic acid 108 
(iso-15:0), phytanic acid (3, 7, 11, 15-tetra methyl-16:0), and the derivative of the latter, pristanic acid, which 109 
are known to bind to nuclear receptors, with subsequent modification of gene expression. Others as phytanic 110 
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acid has been shown to decrease liver triglyceride accumulation in mouse models [21]. Palmitoleic acid 111 
(C16:1 cis 9), has been demonstrated to effect a hormone-like (lipokine) activation of glucose uptake in 112 
muscle cells [22]. Among milk fats, these FA are found in higher concentrations in goat’s milk and are 113 
relevant as contributors to the milk fat melting point and also useful in clinic studies as human intake markers 114 
of milk fat while they are no present in other animal fats [23].  115 
According to this, in the last years, studies have been accomplished resulting in high number of scientific 116 
publications with the aim to reconsider the significant activity of fatty acids present in milk fat and their 117 
effects on human health [9, 24, 25, 26, 27, 11, 12]. 118 
 119 
III.1 CONJUGATED LINOLEIC ACID (CLA) 120 
The generic name CLA is a collective term embracing all positional and geometric isomers of linoleic acid, 121 
which contain a conjugated double bond system. Data from in vitro studies and animal models have been used 122 
to suggest that the isomer C18:2 cis 9, trans 11 (known as rumenic acid, RA) is responsible for CLA 123 
anticarcinogenic and antiatherogenic properties, as well as a multiplicity of potentially beneficial effects on 124 
human health [28, 9, 29, 30, 31, 32]. 125 
Among ruminants, sheep’s milk fat contains one the highest level of CLA, and the major content of C18:1 126 
trans 11 (vaccenic acid, VA), its physiological precursor [33]. In the first studies concerning the total CLA 127 
mean content was described the following order: sheep> cow > goat milk fat, 1.2; 0.7 and 0.6 % of total fatty 128 
acids, respectively [34]. RA is the most abundant isomer and accounts for around 75 % of the total CLA. 129 
From initial studies showing their anticarcinogenic affects as inhibited epithelial tumors in animals [35], a 130 
high number of research works have been performed in the determination of their biological and 131 
physiological properties [20]. The available information on the effects of CLA in cancer cell metabolism 132 
together with their antiproliferative and apoptotic activities [36] place CLA as an interesting compound in 133 
cancer therapy. Even more, recent studies reported that high CLA intake through high fat content dairy 134 
products may reduce the risk of colon-rectal cancer [37]. 135 
There are many possible metabolic pathways involved in the anticancer activity of CLA. It has been 136 
suggested that CLA competes with arachidonic acid (C20:4) in the cyclooxygenase reaction then reducing 137 
the concentration of prostaglandins and thromboxane of the 2-series [38]. CLA can suppress cyclooxygenase 138 
gene expression and reduce the release of pro-inflammatory cytokines such as TNF-alpha and interleukin in 139 
animals [38] as well as also seem to activate the PPARs transcription factors, reduce the initial step in the 140 
activation of NF-kappa B thereby reducing cytokines, adhesion molecules and other induced by stress [39]. 141 
As mentioned, besides RA, other CLA isomers have been associated with several metabolic processes related 142 
to health. Thus the C18:2 trans 10, cis 12, has achieved a great relevance since it have been reported to 143 
promote weight loss [40,9] although it could cause decrease in glucose levels and plasma insulin resistance 144 
[41,42]. RA was tested in breast cancer cell cultures and concluded to act as a human estrogen blocking agent 145 
while C18:2 trans 9, trans 11 inhibits growing of colon cancer cells [43]. 146 
Studies in humans are scarce but in the last years some clinical trials have been carried out using CLA 147 
isomers mixtures. Thus, Tricon et al., [44] had showed that incorporation of RA and C18:2 trans 10, cis 12 148 
into the diet of healthy volunteers affects positively to plasma lipid levels leading to a significant reduction of 149 
the total cholesterol and triacylglycerides (TAG) concentrations mainly associated to RA while C18:2 trans 150 
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10, cis 12 appears not to be as beneficial to the CVD risk markers. Recent studies in obese and overweight 151 
children (6-10 yr old) consuming a CLA enriched chocolate milk, found attenuation in the BMI increment 152 
but did not improve plasma lipids or glucose and decreased HDL cholesterol level [45].  153 
About the other CLA isomers, the C18:2 cis 9 cis 11 has been shown to be also a blocking agent of 154 
estrogen signaling in human breast cancer cells in vitro assays [46]. Other studies have reported the potent 155 
inhibitory effect of C18:2 trans 9 trans 11 on the growth of human colon cancer cells [47] as well as 156 
antiproliferative and pro-apoptotic effects on bovine endothelial cells [48]. However, further research is 157 
needed in this field. 158 
 159 
III.2 TRANS FATTY ACIDS (TFA) 160 
 161 
TFA content in milk fat ranged from 2.5 to 5% of total fatty acids, depending on diet and season. Monoene 162 
TFAs are the main compounds in all species. In ruminant, sheep’s milk presented the highest quantities, after 163 
cows and lately goats milk fat. The pattern of C18:1 trans isomer distribution is however qualitatively 164 
identical in the three species [49]. TFA in dairy fat are not seen as bioactive lipids in a positive sense. But 165 
since TFA have come under scrutiny due to their influence on lipid levels and on other risk factors for CVD, 166 
the question whether all TFA are alike or whether TFA isomers from dairy fat may have metabolic properties 167 
distinct from those of other origins, hydrogenation reaction for instance, has gained increasing relevance 168 
[50]. 169 
The main source of TFA consumed daily by humans is partially hydrogenated vegetable fats and oils, 170 
although these compounds also occur naturally in ruminant milk result of partial biohydrogenation of PUFA 171 
caused by rumen microorganisms. There is a considerable overlap of TFA isomers in fats of ruminant origin 172 
and partially hydrogenated vegetable oils, with many isomers in common. However the isomer profile of 173 
hydrogenated vegetable fats is very different. During the hydrogenation of vegetable fats a wide range of 174 
trans monounsaturated fatty acids are principally formed (e.g. C18:1 trans 9, elaidic acid) while the main 175 
TFA in milk fat is C18:1 trans 11, VA [24]. The importance of VA lies in its already cited role as a precursor 176 
of the main isomer of CLA, rumenic acid (RA) physiologically the most relevant bioactive compound present 177 
in milk fat. This synthesis not only occurs in the bovine mammary gland [51, 52] but also in human and other 178 
animal tissues [53, 54, 55]. The rate of VA to total monoene TFA in milk fat is around 40-60% [56,49,57], 179 
whereas elaidic acid is only present in considerably smaller amounts (average of 5% of the total TFA). In 180 
contrast, the majority of hydrogenated vegetable oils have a TFA profile with a gauss distribution showing 181 
high concentrations of C18:1 trans 9 and trans 10.  182 
Individual TFA isomers could have differing physiological effects [58]. There is evidence of unfavorable 183 
effects of TFA from hydrogenated vegetable oils on LDL and other risk factors of atherosclerosis whereas, the 184 
predominant TFA in milk, VA, would not exert these detrimental effects [24,18]. Most of the studies reported 185 
that the positive association with the risk of CVD could be explained entirely by the intake of TFA from 186 
hydrogenated vegetable oils. Pfeuffer and Scherezenmeir [59] also compiled works addressing the effect of TFA 187 
intake on CVD. Several of the large prospective studies, which established the notion the intake of TFA increases 188 
CVD risk, showed a significant inverse association with intake of animal or dairy TFA, a non-significant inverse 189 
trend or at least no change with increasing intake of TFA from such sources [59].  Recent studies suggest that 190 
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TFA from animal sources did not lead to higher cardiovascular risk [60,61]. Also Tricon et al., [62] and 191 
Wanders et al., [63] found that increments in the concentrations of TVA and RA are not related to CVD  192 
 193 
IV. MINOR LIPID COMPOUNDS 194 
 195 
Milk presents complex lipids as phospholipids and different liposoluble compounds (sterols, -carotene 196 
and vitamins) with biological activity.  197 
Phospholipids are associated with the milk fat globule membrane (MFGM) and account for 0.5-1% of total 198 
milk lipids [64, 65]. Sphingolipids and their active metabolites, ceramides and sphingosines, were determined 199 
as effective bactericidal agents on pathogens and they are reported to have tumor-suppressing properties by 200 
influencing cell proliferation and are highly bioactive compounds with bacteriostatic and cholesterol-201 
lowering properties [9,18,66]. Further, some phospholipids exhibit antioxidative properties in dairy fat 202 
products with low water content [67]. However, to date, only very limited data are available on the 203 
phospholipids content in dairy products and the influence of processing and environmental variables on its 204 
concentration and relative distribution. The phospholipids proportions in the different ruminant milks are 205 
similar: Phosphatidylcholine (35%) phosphatidyl-ethanolamine (30%), and sphingomyelin (25%) are the 206 
major, with smaller amounts of phosphatidylinositol (5%) and phosphatidylserine (3%), [7]. 207 
Other molecules as ether lipids (alkyldiacylglycerols and alkylacylphospholipids) are present in milk lipid 208 
fraction at low amounts but have been also claimed as bioactive components [67]. These compounds are 209 
incorporated and accumulated in cell membranes and thereby influence biochemical and biophysical 210 
processes [18].  211 
The sterol fraction of milk fat and especially the cholesterol is of nutritional interest because high levels of 212 
cholesterol in plasma are associated with an increasing risk of CVD. Nevertheless today is well known 213 
trough analysis of the available epidemiological and clinical data that for the general population, dietary 214 
cholesterol makes no significant contribution to atherosclerosis and risk of CVD [68]. 215 
Cholesterol (about 260-270 mg /100 g fat) is also important for the resorption of fats and its role as 216 
precursor in the synthesis of steroid hormones. Small amounts of other sterols implicated in cholesterol 217 
biosynthesis have also been found in milk fat: lanosterol, dihydrolanosterol, desmosterol, and lathosterol.  218 
 219 
V. FINAL REMARKS  220 
 221 
The public perception of whole milk fat dairy products is a significant challenge that faces the dairy industry 222 
because of their perceived negative effects on human health. Besides, the current nutritional recommendations 223 
for these dairy products are that their consumption should be limited. However, milk is a complex food with a 224 
host of nutrients, and the conclusions from long-term studies and meta-analyses suggest a reduction in risk in 225 
the subjects with the highest dairy consumption relative to those with the lowest intake for almost all-cause 226 
deaths and diseases.  227 
The diversity of milk fat lipids, the variety of bioactive substances that it contains and their physiological 228 
functions remains poorly understood. Therefore, further research is required to establish the contribution of these 229 
bioactive components of milk fat in human health. 230 
 7 
 231 
REFERENCES 232 
[1] Park YW, Juárez M, Ramos M, Haenlein GFW. Physico-chemical characteristics of goat and sheep 233 
milk. Small Rumin. Res. 2007; 68, 88-113. 234 
[2] Lercker, G, Cocchi, M. The milk fat: membranes, composition and structure. Prog Nutr 2010, 12: 235 
183-194. 236 
[3] Spitsberg, VL. Bovine milk fat globule membrane as a potential neutraceutical. J Dairy Sci 2005; 237 
88: 2289-2294. 238 
[4] Fontecha, J, Goudjil H, Ríos JJ, Fraga MJ, Juárez, M. Identity of the major triacylglycerols in ovine 239 
milk fat. Int Dairy J 2005; 15:1217–1224. 240 
[5] Goudjil, H., Fontecha, J., Fraga, M.J., and Juárez, M. TAG composition of ewe’s milk fat. Detection 241 
of foreign fats. J Am Oil Chem Soc 2003; 80: 219-222. 242 
[6] Jensen R.G. (2002). The composition of bovine milk lipids. Journal of Dairy Science. 85:295-350. 243 
[7] McGibbon and Taylor. In: Advanced Dairy Chemistry, Vol. 2, Lipids, 3ª Ed, Fox, P.F. y 244 
McSweeney Eds, Springer: New York 2006; pp.1-42. 245 
[8] Legrand, P. Intérêt nutritionnel des principaux acids gras des lipides laitiers. Sci. Aliments 2008; 246 
28:34-43. 247 
[9] Parodi, PW. Milk fat in human nutrition. Aust. J. Dairy Technol. 2004; 59: 3-59. 248 
[10] Shingfield KJ., Chilliard Y, Toivonen V, Kairenius P, Givens DI. Trans fatty acids and bioactive 249 
lipids in ruminant milk. Adv. Exp. Med. Biol. 2008; 606:3-65. 250 
[11] Steijns, JM. Dairy products and health: Focus on their constituents or on the matrix. Int. Dairy J. 251 
2008; 18: 425–435. 252 
[12] Lecerf, J.M. (2008). Acides gras et maladies cardiovasculaires. Sci. Aliments. 28:53-67. 253 
[13] Dabadie H, Peuchant E, Bernard M, Leruyet P, Mendy F. Moderate intake of myristic acid in sn-2 254 
position has beneficial lipidic effects and enhances DHA of cholesteryl esters in an interventional 255 
study. J. Nutr. Biochem.2005; 16:375-382. 256 
[14] Siri-Tarino PW, Sun Q, Hu FB, Krauss MN. Saturated fat, carbohydrate, and cardiovascular disease. 257 
Am. J. Clin. Nutr. 2010; 91:535-546. 258 
[15] Maier S, Reich E, Martin R, Bachem M, Altug V, Hautman RE, Gschwend JE. (2000) Tributyrin 259 
induces differentiation, growth arrest and apoptosis in androgen-sensitive and androgen-resistant 260 
human prostate cancer cell lines. Int. J. Cancer. 2000; 88: 245-251. 261 
[16] Marten B, Pfeuffer M, Schrezenmeir J. (2006). Medium-chain triglycerides. Int Dairy J 2006; 262 
16(11), 1374-1382.  263 
[17] Blank-Porat D, Gruss-Fischer T, Tarasenko N, Malik Z, Nudelman A, Rephaeli A. The anticancer 264 
prodrugs of butyric acid AN-7 and AN-9, possess antiangiogenic properties. Cancer Letters, 2007; 265 
256(1): p. 39-48. 266 
[18] Parodi PW. Nutritional significance of milk lipids. Advanced Dairy Chemistry, Volumen 2:. Lipids, 267 
3
ª
 edición. Editores: P.F. Fox y P.L.H. McSweeney, Springer, EEUU 2006; pp. 601-639 268 
[19] Neyts, K., Huys, G., Uyttendaele, M., Swings, J., Debevere J. (2000). Incidence and identification of 269 
mesophilic Aeromonas spp. from retail foods. Lett. Appl. Microbiol. 2000; 31: 359-363. 270 
[20] Parodi, P.W. (2008). Milk lipids: their role as potential anti-cancer agents, Sci. Aliments. 28:44-52. 271 
[21] Hallgren B, Niklasson A, Stallberg G, Thorin H. On the occurrence of 1-O(2methoxyalkyl)glycerols 272 
in human colostrums, human milk, cow’s milk, sheep’s milk, human red bone marrow, red cells, 273 
blood plasma and uterine carcinoma. Acta Chem. Scand. 1974; B28:1029-1034. 274 
[22] Olefsky, J. M. Fat Talks, Liver and Muscle Listen. Cell 2008; 134(6): 914-916.  275 
[23] Vlaeminck B, Fievez V, Cabrita ARJ, Fonseca AJM,  Dewhurst RJ. (2006).  Factors affecting odd- 276 
and branched-chain fatty acids in milk: A review. Anim. Feed Sci. Technol. 2006; 131: 389–417. 277 
[24] IDF-International Dairy Federation. Trans fatty acid: Scientific Progress and labelling. Bulletin of 278 
International Dairy Federation 2005; 393. Brusseles. Belgium. 279 
[25] German JB, Dillard CJ. Composition, Structure and Absorption of Milk Lipids: A Source of Energy, 280 
Fat-Soluble Nutrients and Bioactive Molecules. Crit. Rev. Food Sci. Nutr. 2006. 46(1): 57-92. 281 
[26] Akaln S, Gönç S, Ünal G. Functional Properties of Bioactive Components of Milk Fat in 282 
Metabolism. Pak. J. Nutr. 2006; 5: 194-197. 283 
[27] IDF-International Dairy Federation (2007) The health benefits of milk and dairy products. Bulletin 284 
International Dairy Federation2007; 417. Brusseles. Belgium.  285 
[28] Ip MM, Masso-Welch PA, Ip, C. Prevention of mammary cancer with conjugated linoleic acid: role 286 
of stroma and the epithelium. J Mammary Gland Biol Neoplasia 2003; 8: 103-108. 287 
 8 
[29] Lee KW, Lee HJ, Cho HY, Kim YJ. Role of the conjugated linoleic acid in the prevention of cancer. 288 
Crit. Rev. Food Sci. Nutr. 2005; 45:135-144. 289 
[30] Battacharaya A, Banu, J, Rahman M, Causey J, Fernandes G. Biological effects of conjugated 290 
linoleic acids in health and disease. J Nut Biochem 2006; 17: 789-810. 291 
[31] Yurawecz MP, Roach JAG, Sehat N, Mossoba MM, Kramer JKG, Fritsche J, Steinhart H, Ku Y. A 292 
New Conjugated Linoleic Acid Isomer, 7 trans, 9 cis-Octadecadienoic Acid, in Cow Milk, Cheese, 293 
Beef and Human Milk and Adipose Tissue. Lipids 1998; 33: 803-809.  294 
[32] Larsson SC, Bergkvis L, Wolk A. Conjugated linoleic acid intake and breast cancer risk in a 295 
prospective cohort of Swedish women. Am. J. Clin. Nutr. 2009; 90:556-560. 296 
[33] Luna, P, Fontecha J, Juárez M, de la Fuente MA. Effects of a Diet Supplemented with Linseed on 297 
the CLA Content in Ewes Milk Fat. Lipids 2005; 40: 445–454. 298 
[34] Jahreis G, Fritsche J, Kraft J. Species dependent, seasonal, and dietary variation of conjugated 299 
linoleic acid in milk. In: Advances in Conjugated Linoleic Acid, Volume 1, Yurawecz MP, Mossoba 300 
MM, Kramer JKG, Pariza MW, Nelson GJ. Eds., AOCS Press: Champaign Il, 1999; pp. 215-225. 301 
[35] Ha YL, Grimm NK, Pariza MW. Anticarcinogens from fried ground beef: heat altered derivatives of 302 
linoleic acid. Carcinogenesis 1987; 8: 1881-1887. 303 
[36] Ochoa JJ, Farquharson AJ, Grant I, Moffat LE, Heys SD, Wahle KW. Conjugated linoleic acids 304 
(CLAs) decrease prostate cancer cell proliferation: different molecular mechanisms for cis-9, trans-305 
11 and trans-10, cis-12 isomers. Carcinogenesis 2004; 25:1185-91.  306 
[37] Larsson SC, Bergkvist L, Wolk A. High-fat dairy food and conjugated linoleic acid intakes in 307 
relation to colorectal cancer incidence in the Swedish Mammography Cohort. Am. J. Clin. Nutr. 308 
2005; 82:894-900. 309 
[38] Akahoshi A, Koba K, Ichinose F, Kaneko M, Shimoda A, Nonaka K, Yamasaki M, Iwata T, 310 
Yamauchi Y, Tsutsumi K, Sugano M. Dietary protein modulates the effect of CLA on lipid 311 
metabolism in rats. Lipids 2004; 39:25-30.  312 
[39] Cheng WL, Lii CK, Chen HW, Lin TH, Liu KL. Contribution of conjugated linoleic acid to the 313 
suppression of inflammatory responses through the regulation of the NF-kappaB pathway. J. Agric. 314 
Food Chem. 2004; 52:71-8.  315 
[40] Belury MA. Dietary conjugated linoleic acid in health: physiological effects and mechanisms of 316 
action. Ann Reviews Nut 2002; 22: 505-531. 317 
[41] Riserus U, Brismar K, Arner P, Vessby B. Treatment with dietary trans- 10 cis- 12 conjugated 318 
linoleic acid causes isomer-specific insulin resistance in obese men with the metabolic syndrome. 319 
Diabetes Care 2002; 25:1516-1521.  320 
[42] Khanal RC, Dhiman TR. Biosynthesis of conjugated linoleic acid (CLA): A review. Pak. J. Nutr. 321 
2004; 3:72-81. 322 
[43] Coakley M, Johnson MC, McGrath E, Rahman S, Ross RP, Fitzgerald GF, Devery R, Stanton C. 323 
Intestinal Bifidobacteria That Produce trans-9, trans-11 Conjugated Linoleic Acid: A Fatty Acid With 324 
Antiproliferative Activity Against Human Colon SW480 and HT-29 Cancer Cells. Nut Cancer 2006; 325 
56: 95 - 102. 326 
[44] Tricon S, Burdge GC, Kew S, Banerjee T, Russell JJ, Jones EL, Grimble RF, Williams CM, Yaqoob 327 
P, Calder PC. Opposing effects of cis-9, trans-11 and trans-10, cis-12 conjugated linoleic acid on 328 
blood lipids in healthy humans. Am. J. Clin. Nutr. 2004; 80:614-20.  329 
[45] Racine, N.M., Watras, A.C., Carrel, A.L., Allen, D.B., McVean. J.J., Clark, R.R., O'Brien, A.R., 330 
O'Shea, M., Scott, C.E., Schoeller, D.A. Effect of conjugated linoleic acid on body fat accretion in 331 
overweight or obese children. Am. J. Clin. Nutr. 2010; 91: 1157-64. 332 
[46] Tanmahasamut P, Liu J, Hendry LB, Sidell N. (2004). Conjugated Linoleic Acid Blocks Estrogen 333 
Signaling in Human Breast Cancer Cells. J Nut. 2004; 134(3), 674-680.  334 
[47] Beppu F, Hosokawa M, Tanaka L, Kohno H, Tanaka T, Miyashita K. Potent inhibitory effect of 335 
trans9, trans11 isomer of conjugated linoleic acid on the growth of human colon cancer cells. J. 336 
Nutr. Biochem. 2006; 17(12): 830-836.  337 
[48] Lai, KL, Torres-Duarte A, Vanderhoek J. 9-trans,11-trans-CLA: Antiproliferative and proapoptotic 338 
effects on bovine endothelial cells Lipids 2005; 40(11): 1107-1116.  339 
[49] Precht D, Molkentin J, Destaillats F, Wolf RL. (2001). Comparative studies on individual isomeris 340 
18:1 acids in cow, goat and ewe milk fat by low-temperature high-resolution capillary gas-liquid 341 
chromatography. Lipids 2001; 36:827-832. 342 
[50] Glew RH, Chuang LT, Berry T, Okolie H, Crossey MJ, VanderJagt DJ. Lipid Profiles and trans 343 
Fatty Acids in Serum Phospholipids of Semi-nomadic Fulani in Northern Nigeria. J Health Popul 344 
Nutr 2010; 28: 159-166 345 
 9 
[51] Griinari JM, Bauman DE. Biosynthesis of conjugated linoleic acid and its incorporation into meat 346 
and milk in ruminants In: Advances in CLA Research, Volume 1 Yurawecz, M.P., Mossoba, M.M., 347 
Kramer, J.K.G., Pariza, M.W., and Nelson, G.J. Eds, AOCS Press: Champaign, IL, 1999; pp. 180-348 
200. 349 
[52] Field CJ, Blewett, HH, Proctor S, Vine D. Human health benefits of vaccenic acid. Appl. Physiol. 350 
Nutr. Metab. 2009; 34: 979-991. 351 
[53] Turpeinen, A.M., Mutanen, M., Aro, A., Salminen, I., Basu, S., Palmquist, D.L., Griinari J.M. 352 
(2002). Bioconversion of vaccenic acid to conjugated linoleic acid in humans. American Journal 353 
Clinical Nutrition. 76:504-10.  354 
[54] Mosley EE, McGuire MK, Williams JE, McGuire MA. Cis-9, Trans-11 conjugated linoleic acid is 355 
synthesized from vaccenic acid in lactating women. J Nut. 2006; 136:2297-2301. 356 
[55] Kuhnt K, Kraft J, Moeckel P, Jahreis G. Trans-11-18:1 is effectively delta9-desaturated compared 357 
with trans-1218:1 in humans. Br. J. Nutr. 2006; 95:752-761. 358 
[56] Wolff RL. Content and distribution of trans-18:1 acids in ruminant milk and meat fats. Their 359 
importance in European diets and their effect on human milk. J. Am. Oil Chem. Soc. 1995; 72:259–360 
272. 361 
[57] Goudjil, H., Fontecha, J., Luna, P., De la Fuente, M.A., Alonso, L., and Juárez, M. (2004). 362 
Quantitative characterization of unsaturated and trans fatty acids in ewe’s milk fat. Le Lait 2004; 363 
84:473–482. 364 
[58] Anadón A, Martínez-Larrañaga MR, Martínez MA, Ares I, Ramos E, Gómez-Cortés P, Juárez M, 365 
De la Fuente MA. Acute oral safety study of dairy fat rich in trans-10 C18:1 versus vaccenic plus 366 
conjugated linoleic acid in rats. Food Chem. Toxicol. 2010; 48:591–598. 367 
[59] Pfeuffer M, Schrezenmeir J. Impact of trans fatty acids of ruminant origin compared with those from 368 
partially hydrogenated vegetable oils on CHD risk. Int. Dairy J. 2006; 16:1383-1388. 369 
[60] Willett, W.C. (2006). Trans fatty acids and cardiovascular disease – epidemiological data. 370 
Atherosclerosis 2006; 7:5–8. 371 
[61] Willett WC, Mozaffarian D. Ruminant or industrial sources of trans fatty acids: public health issue 372 
or food label skirmish?. Am. J. Clin. Nutr. 2008; 87:515-516. 373 
[62] Tricon S, Burdge GC, Jones EL, Russell JJ, El-Khazen S, Moretti E. Effects of dairy products 374 
naturally enriched with cis-9,trans-11 conjugated linoleic acid on the blood lipid profile in healthy 375 
middle-aged men. Am. J. Clin. Nutr. 2006; 83: 744-753. 376 
[63] Wanders AJ, Leder L, Banga JD, Katan MB, Brouwer IA. A high intake of conjugated linoleic acid 377 
does not affect liver and kidney function tests in healthy human subjects. Food Chem. Toxicol. 378 
2010; 48: 587-590. 379 
[64] Rombaut R, Dewettinck K. Properties, analysis and purification of milk polar lipids. Int. Dairy J. 380 
2006; 16:1362–1373. 381 
[65] Rodríguez-Alcalá LM, Fontecha J. Major lipid classes separation of buttermilk, and cows, goats and 382 
ewes milk by high performance liquid chromatography with an evaporative light scattering detector 383 
focused on the phospholipid fraction. J Chrom A 2010. 1217: 3063–3066. 384 
[66] Gustavsson M, Hodgkinson SC, Fong B, Norris C, Guan JA, Krageloh CU, Breier BH, Davison M, 385 
McJarrow P, Vickers MH. Maternal supplementation with a complex milk lipid mixture during 386 
pregnancy and lactation alters neonatal brain lipid composition but lacks effect on cognitive 387 
function in rats. Nutr. Res. 2010;30: 279-289. 388 
[67] Molkentin J. Occurrence and biochemical characteristics of natural bioactive substances in bovine 389 
milk lipids. Br. J. Nutr.2000; 84:47-53. 390 
[68] McNamara DJ. Dietary cholesterol and atherosclerosis.  Biochim. et Biophys. Acta. 2000; 1529: 391 
310-320. 392 
